Pediatric anxiety disorders: from neuroscience to evidence-based clinical practice by Salum, Giovanni Abrahao et al.
UPDATE ARTICLE
Pediatric anxiety disorders: from neuroscience to
evidence-based clinical practice
Giovanni Abraha˜o Salum,1,2,3 Diogo Arau´jo DeSousa,1 Maria Conceic¸a˜o do Rosa´rio,3,4
Daniel Samuel Pine,5 Gisele Gus Manfro1,2,3
1Anxiety Disorders Outpatient Program for Child and Adolescent Psychiatry, Hospital de Clı´nicas de Porto Alegre (HCPA), Universidade
Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil. 2Graduate Program in Medical Sciences: Psychiatry, UFRGS, Porto Alegre,
RS, Brazil. 3National Science and Technology Institute for Developmental Psychiatry for Children and Adolescents (INCT), Conselho Nacional
de Desenvolvimento Cientı´fico e Tecnolo´gico (CNPq). 4Child and Adolescent Psychiatry Unit, Department of Psychiatry, Universidade Federal
de Sa˜o Paulo (UNIFESP), Sa˜o Paulo, SP, Brazil. 5National Institutes of Mental Health (NIMH), Intramural Research Program, Emotion and
Development Branch.
The objective of this narrative review of the literature is to describe the epidemiology, etiology,
pathophysiology, diagnosis, and treatment of pediatric anxiety disorders. We aim to guide clinicians in
understanding the biology of anxiety disorders and to provide general guidelines for the proper
diagnoses and treatment of these conditions early in life. Anxiety disorders are prevalent, associated
with a number of negative life outcomes, and currently under-recognized and under-treated. The
etiology involves both genes and environmental influences modifying the neural substrate in a
complex interplay. Research on pathophysiology is still in its infancy, but some brain regions, such as
the amygdala and the prefrontal cortex, have been implicated in fear and anxiety. Current practice is
to establish diagnosis based purely on clinical features, derived from clinical interviews with the child,
parents, and teachers. Treatment is effective using medication, cognitive behavioral therapy, or a
combination of both. An introduction to the neuroscience behind anxiety disorders combined with an
evidence-based approach may help clinicians to understand these disorders and treat them properly
in childhood.
Keywords: Child; adolescent; anxiety disorders; obsessive-compulsive disorder
Introduction
Pediatric anxiety disorders refer to a collection of
syndromes characterized by dysfunctional fear and/or
anxiety affecting children and adolescents. Fear can be
defined as a negative emotional state triggered by the
presence of a stimulus that has the potential to cause
immediate harm, while anxiety can be defined as an
emotional state in which the threat is not immediately
present but is anticipated. Both of these emotions are
adaptive and essential for survival. They are accompa-
nied by cognitive representations, physical symptoms,
and behavioral modifications that prepare the individual to
deal with danger (fear response). Fear and anxiety are
considered dysfunctional when intensity, duration, and/or
frequency are not proportional to the eliciting threat, and
thereby cause interference, disabilities, impairment, and/
or distress that are judged clinically excessive.
Anxiety disorders in childhood and adolescence are
associated with a variety of negative outcomes, including
lower educational achievement and failure to attend
university.1 They affect children’s functioning with peers,
school personnel, and family,2,3 are associated with
general psychosocial impairment and disabilities2,3 as
well as with childhood suicide risk even when they are
present in subthreshold levels.4 Pediatric anxiety dis-
orders can also persist and continue to create inter-
ference as the child matures into early adulthood,
especially when associated with depression.5 Later in
life, anxiety disorders are associated with poorer quality
of life,6 suicide,7 and increased mortality due to cardio-
vascular diasease,8 generating a high societal burden
and costs.9 Despite high prevalence and associations
with various negative outcomes, childhood anxiety is
rarely recognized by parents and children as a medical
problem, leading a minority of affected individuals to
receive the care they need.10,11 Furthermore, physicians
can fail to recognize pediatric anxiety in children who do
present for care, and even when anxiety is recognized, it
is frequently treated sub-optimally.9,12,13
The objective of this review was to describe the
epidemiology, etiology, pathophysiology, diagnosis, and
treatment of pediatric anxiety disorders. Given the fact
that anxiety disorders more often co-occur and given the
amount of similarities among these syndromes, this paper
broadly discusses ideas that are relevant to anxiety
disorders as a group.14 Moreover, when considering
individual conditions, the review focuses in depth on four
specific disorders: separation anxiety (SeAD), social
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anxiety (SoAD), generalized anxiety (GAD), and panic
(PD) disorders. Evidence related to specific phobias
(SPs), obsessive-compulsive (OCD), and posttraumatic
stress (PTSD) disorders, when relevant, is also incorpo-
rated though in less detail.
Epidemiology
Prevalence
Anxiety disorders as a group constitute the most common
mental health problem in childhood and adolescence,15
affecting from 2.5 to 30% of youths.15-18 Large variations
in prevalence rates are observed among studies. While
the exact reasons for such variations remain unclear,
most experts attribute them to methodological factors
such as cross-study differences in the age of subjects,
assessment instruments, information source, diagnostic
system used, or variations in the application of the
diagnostic criteria.19-22 Nevertheless, cross-cultural varia-
bility in prevalence rates for anxiety is also likely to occur,
given large differences in risk factor profiles and cultural
beliefs.20,21,23 One reasonable estimate for the global
prevalence of any anxiety disorder in the age range of 3
to 17 years, adjusted for differences in methodological
factors, is 7.2%.24 There is no nationally representative
study for pediatric anxiety in Brazil. The available studies
are limited to cities in the South and Southeast, where
reported prevalence is approximately 5%.25,26
Prevalence for each anxiety disorder is heavily
dependent on the age range of the sample and on the
age of onset patterns of each disorder. SeAD and SP
have the earliest age of onset, with half of the cases
emerging before ages 5 and 8, respectively. SoAD and
OCD typically emerge at early adolescence, with half of
the cases emerging before ages 12 and 14, respectively.
GAD is also common in early adolescence and less well
studied than the other disorders, due to changes in
diagnostic criteria over time. Nevertheless, current data
place the median age of onset in late adolescence, by the
ages of 16-18 years. Agoraphobia, PD and PTSD are low
prevalence conditions in childhood, with higher preva-
lence rates in late adolescence and early adults (median
age of onset 17, 19 and 22, respectively).15 Beyond data
on age trends, anxiety disorders have also been linked to
other demographic factors. Gender is probably the most
frequent demographic correlate of pediatric anxiety. The
female/male gender ratio for almost all anxiety disorder is
2:1 to 3:1.27 Most studies have shown an association
between anxiety and lower instruction levels and worse
socioeconomic status19 but no association has been
found with urbanization or ethnicity.16,19 Table 1 depicts
the prevalence found in two Brazilian studies and other
two representative samples in the United States and
Europe.
Natural course
Prospective studies have shown that 60-80% of adults
with full criteria for anxiety disorders report signs of
earlier, pediatric anxiety.29 Despite the fact that most
affected adults have signs of anxiety as children, in
children followed prospectively, anxiety disorders have
variable natural course. This course typically involves one
of four trajectories: 1) spontaneous long-term remission
(e.g., childhood SeAD that totally disappears in an
otherwise typically developing adolescent who matures
to become a healthy adult); 2) strict homotypic continuity
(e.g., SoAD in childhood persisting into SoAD in adult-
hood); 3) broad homotypic continuity (e.g., SeAD in
childhood predicting PD in adulthood); and 4) sequential
heterotypic comorbidity (e.g., SoAD in childhood predict-
ing latter development of major depression in adult-
hood).15,19,30,31 The latter two trajectories involve a
course that has been characterized as waxing and
waning over time,32 oscillating between threshold and
subthreshold clinical conditions (resulting in high rates of
recurrence rather than chronicity).33
The frequency of each one of these courses is highly
variable from one longitudinal study to another.1,5,29,32,34-42
Broadly we can say that about one-third of anxious
children achieve a long-term remission, another third part
persists with strict or broad anxiety continuity (frequently
accompanied by comorbid disorders), and about one-third
remits from anxiety and develops a sequential heterotypic
comorbidity (mainly with major depression and substance
abuse).1,29,38,40 Among a variety of potential moderators
of the natural history, unfavorable natural courses have
been associated with female gender, symptom severity,
duration of illness, early age of onset, severe avoidance
and associated impairment, parental history of psycho-
pathology, and inhibited temperament.15,43
Etiology and pathophysiology
Mental disorders reflect individual differences in brain
function.31,44,45 Those differences are a result of a
complex combination of factors that ultimately represent
the distal effects of risk genes and/or environmental
components (etiological factors). These etiological risk
factors act on neural circuits (neural substrates) during
brain development and cause quantitative and/or quali-
tative abnormalities in brain functions (pathophysiological
processes). This deviation from typical trajectories of
brain development results in emotional and behavioral
manifestations of psychiatric disorders.46
Genes and environment
Family studies have shown that anxiety disorders are
familial,47,48 whereas twin studies demonstrated that
anxiety disorders are heritable49 and that the proportion
of the phenotypic variability explained by genetic factors
(heritability) for anxiety disorders ranges from 25-60%.49-52
In general, this represents modest heritability for a
psychiatric condition, clearly meaningful but lower than
for highly heritable conditions, such as attention deficit
hyperactivity disorder (ADHD) or autism.53 In addition, one
study54 investigating common childhood psychiatric dis-
orders found that a general set of genes might nonspeci-
fically influence risk for childhood psychiatric disorders,
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whereas two additional sets of genes might influence risk
for two more narrow aspects of illness, reflecting still broad
risks for internalizing and externalizing disorders, respec-
tively. Environmental factors generally involve non-shared
environment effects; meaning factors that tend to make
individuals within a family appear different. Such factors
include aspects of an individual child’s school environ-
ment, the unique stressors he or she experiences, and
their social situation. This is somewhat consistent with the
generalist genes, specialist environment model, i.e., that
common psychopathology mostly share their genetic
liability, but are differentiated by non-shared experiences.
Twin studies that specifically focused on pediatric
anxiety also support the role of both genes and
environment, but the role of the shared environment also
appears to be significant with lower genetic effects.
These types of studies focus more narrowly on specific
presentations of anxiety, in contrast to studies more
broadly examining varieties of psychopathology. These
more narrow studies are incapable of specifying what
genes and environmental factors are particularly note-
worthy for pediatric anxiety. Nevertheless, no twin study
is capable of clarifying how any set of genes and
environments affects the brain unless the study directly
assesses brain function. It is only through effects on the
brain that genes and the environment can ultimately
result in emotional and behavioral abnormalities.48
Candidate gene studies search for specific loci at the
genome. While these have been criticized as being
vulnerable to type I errors, they have identified several
risk genes for anxiety disorders55; however, consistent
with type I errors, a recent review suggested that
available work resulted in ‘‘not a single instance of
replication.’’56 Genome-wide association studies (GWAS)
search the entire genome for signs of association. When
performed properly, these are less vulnerable to type I
errors. To date, five such GWAS have been performed on
anxiety disorders,57-62 though none of these focuses on
children. Among the five, two of them produced sig-
nificant results. Otowa et al.59 found two genes that
achieved genome-wide significance (transmembrane
protein 16B and plakophilin 1), but a subsequent study
failed to replicate these findings in PD patients.58,63 In
another study, a variant in the retinoid-related orphan
receptor alpha gene (RORA) showed genome-wide
significance for PTSD.61 In addition to these five GWAS
investigations, other studies have investigated the excess
of rare copy number variations (CNVs), which are relative
large segments of DNA that are either deleted or
duplicated. In this area, the only study on PD failed to
find genome-wide significance.64
While each of these genetic strategies has advantages,
they also are relatively insensitive to many mechanisms.
For example, available evidence finds signs of complex
gene-environment interplay in anxiety disorders,65-69 and
most research on genetics is poorly suited for capturing
such effects. Genes and environments shape anxiety and
other behaviors through a complex interplay, as it has
been shown through three specific relationships: 1) gene-
environment interaction (genetically influenced sensitivity
to specific environments); 2) gene-environment correla-
tion (genetic influences on individual variation in people’s
exposure to particular environments); 3) epigenetics
(environmental moderation of the effects of genes
through influences in gene expression).70 As under-
standing of genes and the environment accrue, the
complexity of these three sets of relationships is likely
to appear even greater. This suggests that, for anxiety
and other so-called complex behaviors influenced by
multiple factors, the effects of genes are far from
deterministic and cannot be dissociated from the effects
of the child’s environmental conditions. Figure 1 illus-
trates these complex relationships.
Pathophysiological processes and neural substrate
Despite a considerable advance over the last years, little
is known about the neural underpinnings of anxiety
disorders in children and adolescents. Most of the work
in this area focuses on information processing functions
involved in emotional processing (in particular threat
processing) and cognitive control.31,71
The state of knowledge about mental processes
involved in pediatric anxiety is currently limited.
Nevertheless, tentative conclusions about existing rela-
tionships can be drawn. In particular, a set of dysfunc-
tional mental processes has been linked to pediatric
anxiety and associated traits, such as the early-child-
hood temperament of behavioral inhibition. These
dysfunctional processes can be classified into five
groups of information-processing functions: 1) threat-
attention interaction (a tendency for anxious children to
automatically orient their attention towards or away
from threats)72; 2) threat appraisal (a tendency for
anxious children to classify and respond to neutral or
harmless stimuli as if they are dangerous)73; 3) memory
and learning processes (a tendency for anxious indivi-
duals to learn different associations among safe and
dangerous stimuli, as presented in fear conditioning and
extinction experiments)73-75; 4) social evaluative pro-
cesses (a tendency for anxious children to become
concerned about peer evaluation)76; 5) increased
sensitivity to rewards (a tendency for anxiety children
to more strongly alter their behavior when trying to
achieve rewards).77,78
This set of findings suggests that anxiety disorders
involve dysfunctional processes in various emotional and
cognitive processes, each of which is in turn regulated by
several brain regions that may support anxiety disorder
pathophysiology.31,71 Some of the regions include: the
amygdala, several portions of the prefrontal cortex -
particularly the ventrolateral and dorsomedial divisions -
and dysfunctions in the basal ganglia, particularly in
patients with OCD.31,71,79,80
Parenting, life events, and modeling/learning
Several studies have linked various environmental factors
to risk for anxiety. These factors include features of the
home, such as overprotective/over-controlling parenting
GA Salum et al.S6
Rev Bras Psiquiatr. 2013;35(Suppl 1)
style,81,82 as well as features that can occur either within
or outside of the home, such as stressful life events.83,84
Nevertheless, the evidence so far is limited regarding the
direction of these associations. For example, one could
hypothesize that some parents who are themselves
already anxious might also respond to their child’s anxiety
or other signs of vulnerability with parenting practices that
may further reinforce the child’s difficulties, such as
failure to encourage infant social responsiveness.17,85 In
other words, such environmental factors could either
predispose to anxiety in children or children who are at
risk for anxiety may behave in such a way that these
environmental factors are preferentially elicited. Kender &
Baker found that stressful life events, parenting, family,
environment, social support, peer interactions, and
marital quality are significantly influenced by genetic
factors with heritability estimates ranging from 0.07 to
0.3968 - suggesting that associations between anxiety and
parenting or other environmental factors may be geneti-
cally mediated. Other studies found that the effect of
parenting was only partially genetically mediated with an
important role of non-shared environment.86 In addition,
some authors suggest that some fears may arise as a
result of modeling and vicarious learning (i.e., learning
through observation of a parent fearful response in a
threatening situation for her/him)87-89 and verbal transmis-
sion of threat information about novel objects.90,91
However, more experimental studies are needed to better
understand these phenomena.
Research on influences of parenting in psychiatric
disorder illustrates that risk and causality in psychiatry
are extremely complex phenomena.68,69,92-96 In addition,
heterogeneity within anxiety disorders is an important
factor to consider. Two individuals with similar clinical
manifestations may have different dysfunctional
processes, and the same dysfunctional process may be
Figure 1 Schematic representation of the etiological and pathophysiological process related to anxiety disorders. E1, main
environmental effects (E); G1, main genetic effects (G); E2xG2, example of gene environment interaction (GxE; genetic
sensitivity to specific environments); E4RG4, example of epigenetic regulation (Epi; environmental regulation of gene
expression); E5«G5, example of gene environment correlation (rGE; genetic influences on individual variation in people’s
exposure to particular environments). Genes and environments influence the developing brain. Dysfunctional circuits in the
neural substrate result in deficient information processing that ultimately affect individuals’ thoughts, emotions, and/or
behaviors. Extreme dysfunctions in such system produce functional impairment and are interpreted as anxiety disorders.
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responsible for different clinical manifestations. New
initiatives, such as the Research Domain Criteria
(RDoC),97,98 are attempting to clarify the ways in which
underlying neural substrates of mental disorders con-
tribute to dimensional traits that are expressed in specific
behaviors and that cut across current operationalization
of psychopathology.
Dimensional aspects of anxiety
As noted above, fear and anxiety are adaptive responses
to potential threats. The expression of these symptoms
can range from normative to pathological behavior
according to the frequency, intensity, duration and/or
interference in functioning. Therefore, anxiety disorders
may lie at the extreme end of a continuum, rather than
involve symptoms that are exclusive to pathological
conditions. As such, anxiety disorders would represent
a variation in degree but not in kind.99 This would imply a
view of normal and pathological anxiety as falling along a
dimension, with diagnostic thresholds reflecting clinical
and societal burden rather than discontinuous pathophy-
siological states. If this view of anxiety is correct, it would
be quite important to study the normal development of
fears and learn to recognize temperaments that are
closely related to psychopathology in infants. Two such
factors associated with anxiety are behavioral inhibition
and anxiety sensitivity.
Normal development of fears
Because the development of fear circuitry occurs early,
fear responses can be observed very early in life. There
are changes in the context of normative fear over the
course of development, typically from immediate and
concrete stimuli during infancy to anticipatory, abstract,
and more global stimuli that characterize adolescent
fears. During infancy and toddlerhood, most infants
develop a fear of loss and shyness to strangers that
peaks around 8 to 12 months of age, as is expressed by
wariness around unfamiliar people.100,101 These fears
are often followed by separation anxiety that peaks
around 10 to 18 months marked by distress about being
separated from parents. For most children, those fears
disappear around 2 to 3 years of age. Early childhood
(pre-school age) is characterized by normative fears
related to specific threats, such as meteors, clouds,
blood, end of the world, being kidnapped, fairies, loss of
orientation, and dying or death of others. School age is
marked by similar fears, including those directed towards
wind, darkness, water, domestic animals, insects,
ghosts, death, and disease, germs, natural disasters,
traumatic events, harm to self or others, school anxiety,
and performance anxiety. Adolescence is characterized
by fear of negative evaluation and fear of rejection from
peers. All normative fears typically decrease with age
and are transient. In adolescence, stability begins to
become apparent. Increases in prevalence of phobic and
anxiety disorders parallel decreases in normative
fears.71
Behavioral inhibition and anxiety sensitivity
Given the dimensional and developmental nature of
internalizing psychopathology, researchers have consid-
ered whether certain types of temperaments observed
very early in life predict later risk for pediatric anxiety.102
Most of this work has focused on infants who display
heightened reactions to novelty and heightened sensitiv-
ity to stimulus variations. Some such infants mature to
become toddlers who withdraw from novel or unfamiliar
social situations. This group of toddlers is said to manifest
the temperament of behavioral inhibition. This tempera-
ment places the child at risk for SoAD.103,104 A recent
meta-analysis showed that behavioral inhibition was
associated with a seven-fold increased risk for developing
SoAD. Given that 15% of infants are classified as
behaviorally inhibited and about half of them will develop
social anxiety this is one of the most consistent risk
factors for social anxiety.103 Anxiety sensitivity is another
dimensionally distributed trait that, like behavioral inhibi-
tion, has been linked to pediatric anxiety. Anxiety
sensitivity involves beliefs that anxious symptoms will
have harmful physical, psychological, or social conse-
quences to the individual. Some studies suggest that this
trait predicts PD more specifically than other forms of
anxiety, expressed later in life.105,106 Although these
dimensional traits are often seen as risk factors, an
alternative conceptualization is that they represent alter-
native manifestations of overt anxiety disorders, as they
are expressed in younger children.
Clinical manifestations and diagnosis
Despite the dimensional perspective of fear and anxiety,
diagnostic and clinical decisions (e.g., to treat or not to
treat) are categorical and require a classificatory system.
According to the DSM-IV, most of the anxiety disorders
have the same diagnostic criteria for children, adoles-
cents or adults, with some minor variations in presenta-
tion (Table 1).
Screening
Some researchers argue that screening for anxiety
disorder should be universal (applied to every child
irrespective of their symptoms). Despite that, from a
public health perspective, only targeted screening may be
possible, and it is not clear whether universal screening
would be in the best interest of patients. Therefore,
screening may be most helpful among children who
present with complaints about excessive fears, extreme
shyness, frequent worries or rituals - some kind of
emotional distress.
Diagnostic procedures and differential diagnosis
The diagnosis of pediatric anxiety disorder is based on
clinical evaluations. First, normal fears should be differ-
entiated from pathological fears. The best way of doing this
is evaluating whether fears are: 1) developmentally
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expected or not; 2) appear with intensity, duration, and
frequency that is higher than expected for the same age;
and 3) whether the fears result in distress and impairment.
Second, pathological fears should not be better
explained by co-occurring symptoms of another psychia-
tric disorder, by a co-occurring medical disease, or due to
the influences of use/abuse of alcohol and/or other
psychoactive substances (as well as not due to with-
drawal). Therefore, it is crucial to investigate the situa-
tions and context in which the anxiety symptoms
manifest.
Third, primary anxiety should be classified according to
the type of anxiety disorder. Anxiety disorders share in
common several clinical features, namely dysfunctional
cognitions, physical symptoms, and behavioral dysfunc-
tions such as avoidance - one of the core symptomatic
characteristics of all anxiety disorders. However narrowly
defined in diagnostic manuals, specific anxiety disorders
also exhibit a substantial degree of phenotypic hetero-
geneity. Each anxiety disorder has a symptomatic
signature. For treatment purposes, it is useful to
determine the main anxiety disorder as the condition that
produces the greatest distress, impairment, and inter-
ference in the child’s life. Figure 2 describes the core
symptomatic features of the main pediatric anxiety
disorders.
Comorbidity
Pediatric anxiety disorders and other childhood psychia-
tric conditions frequently co-exist in the same patient, a
phenomenon known as comorbidity. In clinically referred
samples, comorbidity is often the rule rather than the
exception,108 with more than half of the patients having
more than one anxiety disorder. In community samples,
anxiety also increases the chance of having additional
psychiatric diagnoses such as major depression (odds
ratio [OR] = 8.2; 95%CI 5.8-12), ADHD (OR = 3.0; 95%CI
2.1-4.3), and oppositional defiant disorder/conduct dis-
order (OR = 3.1; 95%CI 2.2-4.6).109 Anxiety disorders
and substance abuse and dependence in childhood
appear not to be related, but this comorbidity increase
dramatically in adolescents and adults, notably in sub-
jects with social anxiety.110 Therefore a search for
comorbidity is imperative when evaluating children with
anxiety. This includes a specific search for symptoms of
major depression (including suicidal ideation), substance
abuse and dependence, ADHD, and oppositional defiant
disorder. Two other conditions that are not necessarily
disorders but are rather specific behaviors also frequently
present in anxious children. These conditions are
selective mutism, which is the failure to speak in specific
setting despite full use of language at home, and school
refusal, which is the failure to attend to school.
The high degree of comorbidity between anxiety
disorders, as a group, and depression is clearly notable.
In terms of associations between depression and one or
another specific anxiety disorder, evidence is mixed in
terms of whether associations are particularly strong with
specific conditions. Some studies showed particularly
strong associations with GAD, potentially reflecting a
singular higher order structure for the two conditons.111
Other findings appear less specific and more strongly
reflecting developmental variations.38
Assessment
A proper assessment of psychiatric symptoms in child-
hood involves information derived from the child,
parents, and teachers. Particularly for anxiety disorders,
the child information is extremely valuable. Since some
of the symptoms involve emotions, cognitions, and
behaviors that may not involve the parent, it is imperative
to consider the child’s report. Younger children may have
difficulties communicating their symptoms as well as
their associated distress and impairments to the physi-
cian.15 In these cases, parental and teacher information
may be more valuable, but clinicians still should be
vigilant for signs of avoidance expressed by the child.
The clinician should be aware that parents often look for
help with unexplained physical complaints reflecting
heightened arousal (headaches, stomachaches, nau-
sea, vomiting, diarrhea, muscle tension, and difficulty
with sleep) that may indicate an underlying pediatric
anxiety.112
As mentioned above, the diagnosis of any anxiety
disorder is clinical. Although several studies link anxiety
to various biological or genetic factors, the magnitude of
these associations is far too small to be of clinical use
when evaluating individual children. Some structured
interviews and/or rating scales may be helpful to: 1)
screen for anxiety symptoms in non-specialized settings;
2) assess symptom severity; and 3) monitor treatment
gains. Table 2 depicts a variety of clinician, self and
parent rated instruments that may be useful in research
and clinical practice.
Treatment
Both medication and psychotherapy are effective in the
treatment of pediatric anxiety symptoms. Literature is
reviewed below in four specific areas: 1) non-OCD
anxiety disorders (SeAD, SoAD, GAD, and PD); 2)
OCD; 3) PTSD; 4) SP.
Because PD is exceptionally rare in childhood and
adolescence, insufficient evidence exists from controlled
studies to guide treatment.155 Therefore, clinical manage-
ment of PD is often considered as an extension of the
currently available evidence for more common and better
studied anxiety disorders (e.g., SeAD, SoAD and GAD).
SPs are also highly comorbid with other anxiety dis-
orders. When isolated, treatment should use cognitive
behavioral therapy (CBT), with exposure to the feared
object combined with cognitive techniques during the
exposure (whether in vivo, imaginary, or virtual) that
facilitate extinction. Too few studies examine efficacy of
medication in SP to inform recommendations, probably
because CBT, the less invasive interventions, is typically
effective. Evidence regarding the treatment of PTSD and
other consequences of trauma in children most deeply
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examines CBT, where again, evidence of efficacy is
strong.156 Because the few studies examining medication
efficacy in pediatric PTSD are generally equivocal, CBT
should be the first-line treatment in children presenting
with posttraumatic anxiety.157 Due to a more specialized
characterization of the PTSD treatment, this topic will not
be further discussed here. Additional information can be
found elsewhere.157
Medication + psychoeducation
Placebo-controlled clinical trials demonstrate efficacy for
selective serotonin reuptake inhibitors (SSRIs; fluoxetine,
fluvoxamine, paroxetine, and sertraline) in both pediatric
OCD and non-OCD disorders.158 Some trials also
support the use of serotonin and norepinephrine reuptake
inhibitor (SNRI) venlafaxine for non-OCD disorders.158
Figure 2 Algorithm for the diagnostic assessment of pediatric anxiety disorders (based on Salum et al.107). ADHD = attention
deficit hyperactivity disorder; ODD = oppositional defiant disorder
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Regarding tricyclic antidepressants (TADs), one placebo-
controlled study supported the effectiveness of clomipra-
mine in the treatment of OCD,159 as did two studies in
children with school refusal.30 The magnitude of medica-
tion response can be quantified using various metrics.
The so-called number-needed-to-treat (NNT) is emerging
as a current standard. With this metric, estimates are that
approximately four patients should be using the afore-
mentioned drugs in the anxiety disorders treatment in
order to one to achieve clinical response rates (n=14
studies/2,102 patients; medication 58.1% vs. placebo
31.5%; RR = 1.9; NNT = 4).158 This represents a very
strong, robust clinical effect, relative to other conditions.
For example, the NNT in either pediatric or adult
depression for most medication treatments is not half as
potent. There is evidence of the decrease in all anxiety
symptoms with these medications. There is no direct
evidence that any of these medications offer better
responses to treatment or are better tolerated.158
However, a mixed comparison meta-analysis found that
between SSRIs and venlafaxine, venlafaxine was less
efficacious than fluvoxamine and paroxetine and less
tolerated than fluvoxamine, paroxetine, and sertraline.160
Besides the SSRIs and venlafaxine, three studies
about the use of imipramine among patients with anxiety
disorders have demonstrated its effectiveness in non-
OCD disorders.161 However, TADs are considered
secondary choices due to their less favorable adverse
effects and the fact that they require continuous monitor-
ing of blood and cardiac irregularities.158 There is no
evidence supporting the use of benzodiazepines in the
treatment of pediatric anxiety disorders.162
It is vital to emphasize that psychoeducation is an
essential part of the treatment of anxiety disorders.
Psychoeducation includes the explanation of the char-
acteristics of the symptoms, course, treatment strategies,
potential side effects, duration of treatment, etc.
Moreover, it is critical to verify that the patient is using
the medication adequately. More frequent visits in the
beginning of the treatment (weekly, fortnightly) or a
phone-based follow-up are good alternatives to ensure
and increase treatment compliance. An algorithm to
choose among the therapeutic options is depicted in
Figure 3. The most used first-line medications in the
treatment of anxiety disorders, their usage, and adverse
effects are shown in Table 3.
Psychotherapy
CBT is the approach with stronger evidence of effective-
ness as compared to waiting lists or attention control
interventions for both OCD163-165 and non-OCD pediatric
anxiety disorders.164-166 The overall effect size of CBT for
pediatric anxiety in a meta-analysis involving 48 studies
(n=3,740) was 0.66 (compared to passive control 0.77
and to active control 0.39; both significant), demonstrat-
ing a key role of non-specific factors.164 The effect size
for non-CBT interventions was not significant.164
Treatment target CBT (specific to one anxiety disorder)
and individual treatments (as opposed to groups) had a
larger effect size than treatment targeting several anxiety
disorders and group CBT.164 Clinical trials have also
shown that CBT may have better results for treating OCD
when family members are involved to reduce the levels of
family accommodation (the different ways that family
members may respond to the patient’s symptoms by
facilitating avoidance, assisting on ritualistic behaviors, or
inadvertently participating in rituals).167
Combined treatment
Two large studies have evaluated the combined treatment
as compared to the monotherapy and placebo compo-
nents.108,168 For non-OCD anxiety disorders, the
CBT+sertraline combined treatment was more effective
than both monotherapy conditions and the placebo
condition.108 For OCD, the combined treatment was more
effective than the sertraline monotherapy and the placebo
conditions, but there was no difference between the
combined treatment and the CBT monotherapy.168 Data
from this study investigating moderator factors of these
therapy conditions have demonstrated that, for patients
with a family history of OCD, the combined treatment or the
sertraline monotherapy condition are preferable.169
Conversely, for patients with comorbid OCD and tic
disorders - a frequent comorbidity -, the combined
treatment or the CBT are preferable.170 Moreover, in
these cases, the combination of SSRI and alpha-adrener-
gic agonists or anti-psychotics might be an option.171
Other treatments and future perspectives
Innovative treatments for anxiety disorders have been
developed from the neuroscience field, such as the d-
cycloserine combined with behavioral techniques172 and
the attentional bias modification treatment.173,174
Regulators of glutamatergic neurotransmission, such as
riluzole175 and N-acetylcysteine,176 have also been
examined in adolescents diagnosed with OCD.
Although promising, these treatments do not yet present
long-term outcomes and are currently restricted to
research settings.
Studies in adults and children have demonstrated that
interventions focusing on the individual’s lifestyle, such as
physical exercise, are associated with improvements in
anxiety and depressive symptoms,177-179 and exercise
should be encouraged. Evidence from studies with adult
samples have also stated that complementary treatments
with kava,180 valerian,181 passiflora,182 meditation,183 or
healing touch184 have inconclusive benefits in the
treatment of anxiety disorders, with not enough evidence
to recommend their use.
Monitoring, refractoriness, referring
Due to the unfavorable natural history of anxiety disorders,
it is highly important to monitor anxiety symptoms and
potential side effects objectively and systematically.185
Some studies have suggested that SSRI treatments might
lead to an increase in suicidality among children. Further
Pediatric anxiety disorders S13
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Figure 3 Algorithm for the management of pediatric anxiety disorders (based on Salum et al.107). CBT = cognitive behavioral
therapy; GAD = generalized anxiety disorder; OCD = obsessive-compulsive disorder; PD = panic disorder; PTSD =
posttraumatic stress disorder; SeAD = separation anxiety disorder; SoAD = social anxiety disorder; SP = specific phobias;
SNRI = serotonin and norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor
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studies have demonstrated that the benefits of treating
anxiety disorders largely outweigh the potential risks
related to the increase of suicidal ideation, which, although
serious, is a rare event in the treatment of patients with
anxiety disorders.186 Nevertheless we underscore the
need to monitor continuously suicidal thoughts and suicidal
behaviors in this population.
There is a lack of consistent evidence regarding the
best way to deal with refractory anxiety disorders or the
best sequence of treatments to be applied. Overall, the
recommendation is to optimize the medication dosage,
since some patients only respond at higher doses (e.g.,
slow metabolizers, OCD patients). If there is no response
after 4 to 6 weeks of treatment and after the dosage
optimization, it is possible to: 1) change medications
within the same class (e.g., fluoxetine for sertraline) or 2)
change the previous medication for another one from a
different class (e.g., fluoxetine for venlafaxine).187
In public health systems, specialized treatment is
recommended in cases in which: 1) patients have shown
refractoriness to two previous therapeutic alternatives; 2)
patients have severe chronic disorders, including high
level of impairment, unusually frequent avoidance beha-
viors and agoraphobia that do not respond to psycho-
tropic and clearly require behavioral therapy or CBT; and
3) patients present persistent suicidal ideation.
Preschool children treatment and prevention
Most of the currently available evidence regarding the
treatment of pediatric anxiety disorders is based on
studies with school-aged children. However, there is a
current trend to offer treatment for younger children
(preschoolers), hoping that earlier diagnoses may pre-
vent later psychiatric disorders. Parental training with
CBT protocols and the treatment of mood and anxiety
disorders in clinically-ill parents are suggested by some
authors.188 Although scarce, there is promising evidence
that treatments based on existing therapies (CBT,
parental training, and pharmacotherapy), adapted to at-
risk populations, i.e., highly symptomatic children, but still
not meeting criteria for the diagnosis of anxiety disorders,
or children with first-degree relatives diagnosed with
anxiety disorders, result in preventing and reducing the
severity of these disorders.189
This is a general overview about pediatric anxiety
disorders. More specific and comprehensive reviews
about the following topics can be found in the literature:
prevalence,15,18-20 behavioral inhibition,190-192 behavioral
genetics,48,52 genetics,55,56,193,194 gene vs. environment
interplay,52,70 pathophysiology,31,71 neural substrates,71
normal development of fears,195 psychopharmacological
treatment,196-198 and CBT.164,199-201
Conclusions
Anxiety disorders are prevalent, associated with a
number of negative life outcomes, and currently under-
recognized and under-treated. The etiology involves both
genes and environmental factors in a complex interplay.
Pathophysiology is still in its infancy, but some brain
regions such as the amygdala and the prefrontal cortex
potentially play a key role to explain individual differences
related to fear and anxiety. The diagnosis is clinical and
involves clinical interviews with the child, parents, and
teachers. Treatment is effective using medication, CBT,
or a combination of strategies.
Disclosure
Giovanni Abraha˜o Salum receives a post-doctoral fellow-
ship from Coordenac¸a˜o de Aperfeic¸oamento de Pessoal
de Nı´vel Superior (CAPES) and Fundac¸a˜o de Amparo a`
Pesquisa do Estado do Rio Grande do Sul (FAPERGS).
Diogo Arau´jo DeSouza receives a doctoral fellowship
from Conselho Nacional de Desenvolvimento Cientı´fico e
Tecnolo´gico (CNPq). Maria Conceic¸a˜o do Rosa´rio
receives research support from Brazilian government
institutions (CNPq) and has worked in the last 5 years as
a speaker for the companies Novartis and Shire. Daniel
Pine declares no potential conflicts of interest. Gisele Gus
Manfro receives research support from Brazilian govern-
ment institutions (CNPq, FAPERGS and Fundo de
Incentivo a` Pesquisa - Hospital de Clı´nicas de Porto
Alegre - FIPE-HCPA).
References
1 Woodward LJ, Fergusson DM. Life course outcomes of young
people with anxiety disorders in adolescence. J Am Acad Child
Adolesc Psychiatry. 2001;40:1086-93.
2 Essau CA, Conradt J, Petermann F. Frequency, comorbidity, and
psychosocial impairment of anxiety disorders in German adoles-
cents. J Anxiety Disord. 2000;14:263-79.
3 Ezpeleta L, Keeler G, Erkanli A, Costello EJ, Angold A.
Epidemiology of psychiatric disability in childhood and adolescence.
J Child Psychol Psychiatry. 2001;42:901-14.
4 Bala´zs J, Miklo´si M, Kereszte´ny A, Hoven CW, Carli V, Wasserman
C, et al. Adolescent subthreshold-depression and anxiety: psycho-
pathology, functional impairment and increased suicide risk. J Child
Psychol Psychiatry. 2013;54:670-7.
5 Last CG, Hansen C, Franco N. Anxious children in adulthood: a
prospective study of adjustment. J Am Acad Child Adolesc
Psychiatry. 1997;36:645-52.
6 Olatunji BO, Cisler JM, Tolin DF. Quality of life in the anxiety
disorders: a meta-analytic review. Clin Psychol Rev. 2007;27:572-81.
7 Nock MK, Hwang I, Sampson NA, Kessler RC. Mental disorders,
comorbidity and suicidal behavior: results from the National
Comorbidity Survey Replication. Mol Psychiatry. 2010;15:868-76.
8 Roest AM, Martens EJ, de Jonge P, Denollet J. Anxiety and risk of
incident coronary heart disease: a meta-analysis. J Am Coll Cardiol.
2010;56:38-46.
9 Baldwin DS, Pallanti S, Zwanzger P. Developing a European
research network to address unmet needs in anxiety disorders.
Neurosci Biobehav Rev. 2013 Jan 10. [Epub ahead of print]
10 Ranta K, Kaltiala-Heino R, Rantanen P, Marttunen M. Social phobia
in Finnish general adolescent population: prevalence, comorbidity,
individual and family correlates, and service use. Depress Anxiety.
2009;26:528-36.
11 Merikangas KR, He JP, Brody D, Fisher PW, Bourdon K, Koretz
DS. Prevalence and treatment of mental disorders among US
children in the 2001-2004 NHANES. Pediatrics. 2010;125:75-81.
12 Chavira DA, Stein MB, Bailey K, Stein MT. Child anxiety in primary
care: prevalent but untreated. Depress Anxiety. 2004;20:155-64.
13 Wren FJ, Scholle SH, Heo J, Comer DM. Pediatric mood and
anxiety syndromes in primary care: who gets identified? Int J
Psychiatry Med. 2003;33:1-16.
GA Salum et al.S16
Rev Bras Psiquiatr. 2013;35(Suppl 1)
14 Rutter M. Research review: child psychiatric diagnosis and
classification: concepts, findings, challenges and potential. J Child
Psychol Psychiatry. 2011;52:647-60.
15 Beesdo-Baum K, Knappe S. Developmental epidemiology of
anxiety disorders. Child Adolesc Psychiatr Clin N Am.
2012;21:457-78.
16 Merikangas KR, He JP, Burstein M, Swanson SA, Avenevoli S, Cui
L, et al. Lifetime prevalence of mental disorders in U.S. adoles-
cents: results from the National Comorbidity Survey Replication--
Adolescent Supplement (NCS-A). J Am Acad Child Adolesc
Psychiatry. 2010;49:980-9.
17 Rapee RM, Schniering CA, Hudson JL. Anxiety disorders during
childhood and adolescence: origins and treatment. Annu Rev Clin
Psychol. 2009;5:311-41.
18 Costello EJ, Egger HL, Angold A. The developmental epidemiology
of anxiety disorders: phenomenology, prevalence, and comorbidity.
Child Adolesc Psychiatr Clin N Am. 2005;14:631-48.
19 Beesdo K, Knappe S, Pine DS. Anxiety and anxiety disorders in
children and adolescents: developmental issues and implications
for DSM-V. Psychiatr Clin North Am. 2009;32:483-524.
20 Baxter AJ, Scott KM, Vos T, Whiteford HA. Global prevalence of
anxiety disorders: a systematic review and meta-regression.
Psychol Med. 2013;43:897-910.
21 Somers JM, Goldner EM, Waraich P, Hsu L. Prevalence and
incidence studies of anxiety disorders: a systematic review of the
literature. Can J Psychiatry. 2006;51:100-13.
22 Adornetto C, Suppiger A, In-Albon T, Neuschwander M, Schneider
S. Concordances and discrepancies between ICD-10 and DSM-IV
criteria for anxiety disorders in childhood and adolescence. Child
Adolesc Psychiatry Ment Health. 2012;6:40.
23 Salum GA, Isolan LR, Bosa VL, Tocchetto AG, Teche SP, Schuch I,
et al. The multidimensional evaluation and treatment of anxiety in
children and adolescents: rationale, design, methods and prelimin-
ary findings. Rev Bras Psiquiatr. 2011;33:181-95.
24 Baxter AJ, Charlson FJ, Somerville AJ, Whiteford HA. Mental
disorders as risk factors: assessing the evidence for the Global
Burden of Disease Study. BMC Med. 2011;9:134.
25 Anselmi L, Fleitlich-Bilyk B, Menezes AM, Araujo CL, Rohde LA.
Prevalence of psychiatric disorders in a Brazilian birth cohort of 11-
year-olds. Soc Psychiatry Psychiatr Epidemiol. 2010;45:135-42.
26 Fleitlich-Bilyk B, Goodman R. Prevalence of child and adolescent
psychiatric disorders in southeast Brazil. J Am Acad Child Adolesc
Psychiatry. 2004;43:727-34.
27 Craske MG. Origins of phobias and anxiety disorders: why more
women than men? Amsterdam: Elsevier; 2003.
28 American Psychiatric Association. Diagnostic and statistical manual
of mental disorders - DSM-IV-TRH. 4th ed. Arlington: American
Psychiatric Publishing; 1994.
29 Gregory AM, Caspi A, Moffitt TE, Koenen K, Eley TC, Poulton R.
Juvenile mental health histories of adults with anxiety disorders. Am
J Psychiatry. 2007;164:301-8.
30 Pine DS, Klein RG. Anxiety disorders. In: Rutter M, Bishop DVM,
Pine DS, Scott S, Stevenson J, Taylor E, Thapar A , editors.
Rutter’s child and adolescent psychiatry. 5th ed. Oxford: Blackwell
Publishing Ltd; 2009. p. 628-647.
31 Pine DS. Research review: a neuroscience framework for pediatric
anxiety disorders. J Child Psychol Psychiatry. 2007;48:631-48.
32 Wittchen HU, Lieb R, Pfister H, Schuster P. The waxing and waning
of mental disorders: evaluating the stability of syndromes of mental
disorders in the population. Compr Psychiatry. 2000;41:122-32.
33 Kessler RC, Avenevoli S, Costello EJ, Georgiades K, Green JG,
Gruber MJ, et al. Prevalence, persistence, and sociodemographic
correlates of DSM-IV disorders in the National Comorbidity Survey
Replication Adolescent Supplement. Arch Gen Psychiatry.
2012;69:372-80.
34 Pine DS, Cohen P, Gurley D, Brook J, Ma Y. The risk for early-
adulthood anxiety and depressive disorders in adolescents with
anxiety and depressive disorders. Arch Gen Psychiatry.
1998;55:56-64.
35 Copeland WE, Shanahan L, Costello EJ, Angold A. Childhood and
adolescent psychiatric disorders as predictors of young adult
disorders. Arch Gen Psychiatry. 2009;66:764-72.
36 Bittner A, Egger HL, Erkanli A, Jane Costello E, Foley DL, Angold A.
What do childhood anxiety disorders predict? J Child Psychol
Psychiatry. 2007;48:1174-83.
37 Angst J, Vollrath M. The natural history of anxiety disorders. Acta
Psychiatr Scand. 1991;84:446-52.
38 Beesdo K, Pine DS, Lieb R, Wittchen HU. Incidence and risk
patterns of anxiety and depressive disorders and categorization of
generalized anxiety disorder. Arch Gen Psychiatry. 2010;67:47-57.
39 Last CG, Perrin S, Hersen M, Kazdin AE. A prospective study of
childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry.
1996;35:1502-10.
40 Pine DS, Cohen P, Brook J. Adolescent fears as predictors of
depression. Biol Psychiatry. 2001;50:721-4.
41 Kim-Cohen J, Caspi A, Moffitt TE, Harrington H, Milne BJ, Poulton
R. Prior juvenile diagnoses in adults with mental disorder:
developmental follow-back of a prospective-longitudinal cohort.
Arch Gen Psychiatry. 2003;60:709-17.
42 Colman I, Wadsworth ME, Croudace TJ, Jones PB. Forty-year
psychiatric outcomes following assessment for internalizing dis-
order in adolescence. Am J Psychiatry. 2007;164:126-33.
43 Scholten WD, Batelaan NM, van Balkom AJ, Wjh Penninx B, Smit
JH, van Oppen P. Recurrence of anxiety disorders and its
predictors. J Affect Disord. 2013;147:180-5.
44 Insel TR. Disruptive insights in psychiatry: transforming a clinical
discipline. J Clin Invest. 2009;119:700-5.
45 Insel TR, Quirion R. Psychiatry as a clinical neuroscience discipline.
JAMA. 2005;294:2221-4.
46 Levitt P, March J. NIMH Council Workgroup on Neurodevelopment:
Update on Activities and Workgroup Recommendations. Bethesda,
MD: 2008.
47 Skre I, Onstad S, Edvardsen J, Torgersen S, Kringlen E. A family
study of anxiety disorders: familial transmission and relationship to
mood disorder and psychoactive substance use disorder. Acta
Psychiatr Scand. 1994;90:366-74.
48 Gregory AM, Eley TC. Genetic influences on anxiety in children:
what we’ve learned and where we’re heading. Clin Child Family
Psychol Rev. 2007;10:199-212.
49 Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of
the genetic epidemiology of anxiety disorders. American J
Psychiatry. 2001;158:1568-78.
50 Topolski TD, Hewitt JK, Eaves L, Meyer JM, Silberg JL, Simonoff E,
et al. Genetic and environmental influences on ratings of manifest
anxiety by parents and children. J Anxiety Disord. 1999;13:371-97.
51 Hettema JM, Prescott CA, Myers JM, Neale MC, Kendler KS. The
structure of genetic and environmental risk factors for anxiety
disorders in men and women. Arch Gen Psychiatry. 2005;62:182-9.
52 Franic´ S, Middeldorp CM, Dolan CV, Ligthart L, Boomsma DI.
Childhood and adolescent anxiety and depression: beyond herit-
ability. J Am Acad Child Adolesc Psychiatry. 2010;49:820-9.
53 Rommelse NN, Franke B, Geurts HM, Hartman CA, Buitelaar JK.
Shared heritability of attention-deficit/hyperactivity disorder and
autism spectrum disorder. Eur Child Adolesc Psychiatry.
2010;19:281-95.
54 Lahey BB, Van Hulle CA, Singh AL, Waldman ID, Rathouz PJ.
Higher-order genetic and environmental structure of prevalent
forms of child and adolescent psychopathology. Arch Gen
Psychiatry. 2011;68:181-9.
55 Sakolsky DJ, McCracken JT, Nurmi EL. Genetics of pediatric anxiety
disorders. Child Adolesc Psychiatr Clin N Am. 2012;21:479-500.
56 McGrath LM, Weill S, Robinson EB, Macrae R, Smoller JW.
Bringing a developmental perspective to anxiety genetics. Dev
Psychopathol. 2012;24:1179-93.
57 Erhardt A, Czibere L, Roeske D, Lucae S, Unschuld PG, Ripke S,
et al. TMEM132D, a new candidate for anxiety phenotypes:
evidence from human and mouse studies. Mol Psychiatry.
2011;16:647-63.
58 Otowa T, Tanii H, Sugaya N, Yoshida E, Inoue K, Yasuda S, et al.
Replication of a genome-wide association study of panic disorder in
a Japanese population. J Hum Genet. 2010;55:91-6.
59 Otowa T, Yoshida E, Sugaya N, Yasuda S, Nishimura Y, Inoue K,
et al. Genome-wide association study of panic disorder in the
Japanese population. J Hum Genet. 2009;54:122-6.
Pediatric anxiety disorders S17
Rev Bras Psiquiatr. 2013;35(Suppl 1)
60 Stewart SE, Yu D, Scharf JM, Neale BM, Fagerness JA, Mathews
CA, et al. Genome-wide association study of obsessive-compulsive
disorder. Mol Psychiatry. 2012 Aug 14. [Epub ahead of print]
61 Logue MW, Baldwin C, Guffanti G, Melista E, Wolf EJ, Reardon AF,
et al. A genome-wide association study of post-traumatic stress
disorder identifies the retinoid-related orphan receptor alpha
(RORA) gene as a significant risk locus. Mol Psychiatry. 2012
Aug 7. [Epub ahead of print]
62 Gregersen N, Dahl HA, Buttenschon HN, Nyegaard M, Hedemand
A, Als TD, et al. A genome-wide study of panic disorder suggests
the amiloride-sensitive cation channel 1 as a candidate gene. Eur J
Hum Genet. 2012;20:84-90.
63 Otowa T, Kawamura Y, Nishida N, Sugaya N, Koike A, Yoshida E,
et al. Meta-analysis of genome-wide association studies for panic
disorder in the Japanese population. Transl Psychiatry.
2012;2:e186.
64 Kawamura Y, Otowa T, Koike A, Sugaya N, Yoshida E, Yasuda S,
et al. A genome-wide CNV association study on panic disorder in a
Japanese population. J Hum Genet. 2011;56:852-6.
65 Lau JY, Gregory AM, Goldwin MA, Pine DS, Eley TC. Assessing
gene-environment interactions on anxiety symptom subtypes
across childhood and adolescence. Dev Psychopathol.
2007;19:1129-46.
66 Hicks BM, DiRago AC, Iacono WG, McGue M. Gene-environment
interplay in internalizing disorders: consistent findings across six
environmental risk factors. J Child Psychol Psychiatry.
2009;50:1309-17.
67 Narusyte J, Neiderhiser JM, D’Onofrio BM, Reiss D, Spotts EL,
Ganiban J, et al. Testing different types of genotype-environment
correlation: an extended children-of-twins model. Dev Psychol.
2008;44:1591-603.
68 Kendler KS, Baker JH. Genetic influences on measures of the
environment: a systematic review. Psychol Med. 2007;37:615-26.
69 Kendler KS. Parenting: a genetic-epidemiologic perspective. Am J
Psychiatry. 1996;153:11-20.
70 Rutter M, Moffitt TE, Caspi A. Gene-environment interplay and
psychopathology: multiple varieties but real effects. J Child Psychol
Psychiatry. 2006;47:226-61.
71 Blackford JU, Pine DS. Neural substrates of childhood anxiety
disorders: a review of neuroimaging findings. Child Adolesc
Psychiatr Clin N Am. 2012;21:501-25.
72 Shechner T, Britton JC, Pe´rez-Edgar K, Bar-Haim Y, Ernst M, Fox
NA, et al. Attention biases, anxiety, and development: toward or
away from threats or rewards? Depress Anxiety. 2012;29:282-94.
73 Britton JC, Lissek S, Grillon C, Norcross MA, Pine DS.
Development of anxiety: the role of threat appraisal and fear
learning. Depress Anxiety. 2011;28:5-17.
74 Lissek S. Toward an account of clinical anxiety predicated on basic,
neurally mapped mechanisms of Pavlovian fear-learning: the case
for conditioned overgeneralization. Depress Anxiety. 2012;29:
257-63.
75 Kheirbek MA, Klemenhagen KC, Sahay A, Hen R. Neurogenesis
and generalization: a new approach to stratify and treat anxiety
disorders. Nat Neurosci. 2012;15:1613-20.
76 Guyer AE, Lau JY, McClure-Tone EB, Parrish J, Shiffrin ND,
Reynolds RC, et al. Amygdala and ventrolateral prefrontal cortex
function during anticipated peer evaluation in pediatric social
anxiety. Arch Gen Psychiatry. 2008;65:1303-12.
77 Guyer AE, Choate VR, Detloff A, Benson B, Nelson EE, Perez-
Edgar K, et al. Striatal functional alteration during incentive
anticipation in pediatric anxiety disorders. Am J Psychiatry.
2012;169:205-12.
78 Guyer AE, Nelson EE, Perez-Edgar K, Hardin MG, Roberson-Nay
R, Monk CS, et al. Striatal functional alteration in adolescents
characterized by early childhood behavioral inhibition. J Neurosci.
2006;26:6399-405.
79 Mana S, Paille`re Martinot ML, Martinot JL. Brain imaging findings in
children and adolescents with mental disorders: a cross-sectional
review. Eur Psychiatry. 2010;25:345-54.
80 Milad MR, Rauch SL. Obsessive-compulsive disorder: beyond
segregated cortico-striatal pathways. Trends Cogn Sci. 2012;16:
43-51.
81 Rapee RM. Potential role of childrearing practices in the develop-
ment of anxiety and depression. Clin Psychol Rev. 1997;17:47-67.
82 McLeod BD, Wood JJ, Weisz JR. Examining the association
between parenting and childhood anxiety: a meta-analysis. Clin
Psychol Rev. 2007;27:155-72.
83 Allen JL, Rapee RM, Sandberg S. Severe life events and chronic
adversities as antecedents to anxiety in children: a matched control
study. J Abnorm Child Psychol. 2008;36:1047-56.
84 Eley TC, Stevenson J. Specific life events and chronic experiences
differentially associated with depression and anxiety in young twins.
J Abnorm Child Psychol. 2000;28:383-94.
85 Murray L, Creswell C, Cooper PJ. The development of anxiety
disorders in childhood: an integrative review. Psychol Med.
2009;39:1413-23.
86 Otowa T, Gardner CO, Kendler KS, Hettema JM. Parenting and risk
for mood, anxiety and substance use disorders: a study in
population-based male twins. Soc Psychiatry Psychiatr Epidemiol.
2013 Jan 24. [Epub ahead of print]
87 de Rosnay M, Cooper PJ, Tsigaras N, Murray L. Transmission of
social anxiety from mother to infant: an experimental study using a
social referencing paradigm. Behav Res Ther. 2006;44:1165-75.
88 Gerull FC, Rapee RM. Mother knows best: effects of maternal
modelling on the acquisition of fear and avoidance behaviour in
toddlers. Behav Res Ther. 2002;40:279-87.
89 Murray L, de Rosnay M, Pearson J, Bergeron C, Schofield E,
Royal-Lawson M, et al. Intergenerational transmission of social
anxiety: the role of social referencing processes in infancy. Child
Dev. 2008;79:1049-64.
90 Field AP. Is conditioning a useful framework for understanding the
development and treatment of phobias? Clin Psychol Rev.
2006;26:857-75.
91 Field AP, Lawson J. Fear information and the development of fears
during childhood: effects on implicit fear responses and behavioural
avoidance. Behav Res Ther. 2003;41:1277-93.
92 Kraemer HC, Kazdin AE, Offord DR, Kessler RC, Jensen PS,
Kupfer DJ. Coming to terms with the terms of risk. Arch Gen
Psychiatry. 1997;54:337-43.
93 Kraemer HC, Stice E, Kazdin A, Offord D, Kupfer D. How do risk
factors work together? Mediators, moderators, and independent,
overlapping, and proxy risk factors. Am J Psychiatry. 2001;158:
848-56.
94 Kendler KS. ‘‘A gene for...’’: the nature of gene action in psychiatric
disorders. Am J Psychiatry. 2005;162:1243-52.
95 Kendler KS. Preparing for gene discovery: a further agenda for
psychiatry. Arch Gen Psychiatry. 1999;56:554-5.
96 Kendler KS. Explanatory models for psychiatric illness. Am J
Psychiatry. 2008;165:695-702.
97 Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, et al.
Research Domain Criteria (RDoC): toward a new classification
framework for research on mental disorders. Am J Psychiatry.
2010;167:748-51.
98 Sanislow CA, Pine DS, Quinn KJ, Kozak MJ, Garvey MA, Heinssen
RK, et al. Developing constructs for psychopathology research:
research domain criteria. J Abnorm Psychol. 2010;119:631-9.
99 Coghill D, Sonuga-Barke EJ. Annual research review: categories
versus dimensions in the classification and conceptualisation of
child and adolescent mental disorders--implications of recent
empirical study. J Child Psychol Psychiatry. 2012;53:469-89.
100 Skarin K. Cognitive and contextual determinants of stranger fear in
six- and eleven-month-old infants. Child Dev. 1977;48:537-44.
101 Thompson RA, Limber SP. ‘‘Social anxiety’’ in infancy: stranger and
separation reactions. In: Leitenberg H, editor. Handbook of social
and evaluation anxiety. New York: Plenum Press; 1990. p. 85-137.
102 Kagan J, Snidman N, Zentner M, Peterson E. Infant temperament
and anxious symptoms in school age children. Dev Psychopathol.
1999;11:209-24.
103 Clauss JA, Blackford JU. Behavioral inhibition and risk for
developing social anxiety disorder: a meta-analytic study. J Am
Acad Child Adolesc Psychiatry. 2012;51:1066-75.
104 Degnan KA, Almas AN, Fox NA. Temperament and the environ-
ment in the etiology of childhood anxiety. J Child Psychol
Psychiatry. 2010;51:497-517.
105 Noel VA, Francis SE. A meta-analytic review of the role of child
anxiety sensitivity in child anxiety. J Abnorm Child Psychol.
2011;39:721-33.
GA Salum et al.S18
Rev Bras Psiquiatr. 2013;35(Suppl 1)
106 Olatunji BO, Wolitzky-Taylor KB. Anxiety sensitivity and the anxiety
disorders: a meta-analytic review and synthesis. Psychol Bull.
2009;135:974-99.
107 Salum GA, Alvarenga PG, Manfro GG. Transtornos de ansiedade e
transtorno obsessivo-compulsivo. In: Polanczyk GV, Lamberte
MTMR, editors. Psiquiatria da infaˆncia e adolesceˆncia. Sa˜o
Paulo: Manole; 2012.
108 Walkup JT, Albano AM, Piacentini J, Birmaher B, Compton SN,
Sherrill JT, et al. Cognitive behavioral therapy, sertraline, or a
combination in childhood anxiety. N Engl J Med. 2008;359:2753-66.
109 Angold A, Costello EJ, Erkanli A. Comorbidity. J Child Psychol
Psychiatry. 1999;40:57-87.
110 Wolitzky-Taylor K, Bobova L, Zinbarg RE, Mineka S, Craske MG.
Longitudinal investigation of the impact of anxiety and mood
disorders in adolescence on subsequent substance use disorder
onset and vice versa. Addict Behav. 2012;37:982-5.
111 Moffitt TE, Harrington H, Caspi A, Kim-Cohen J, Goldberg D,
Gregory AM, et al. Depression and generalized anxiety disorder:
cumulative and sequential comorbidity in a birth cohort followed
prospectively to age 32 years. Arch Gen Psychiatry. 2007;64:651-
60.
112 Gandhi B, Cheek S, Campo JV. Anxiety in the pediatric medical
setting. Child Adolesc Psychiatr Clin N Am. 2012;21:643-53.
113 Brasil HHA. Development of the Brazilian version of K-SADS-PL
(Schedule for Affective Disorders and Schizophrenia for School
Aged Children Present and Lifetime Version) and study of
psychometric properties [dissertation]. Sa˜o Paulo: Universidade
Federal de Sa˜o Paulo; 2003.
114 Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, et al.
Schedule for Affective Disorders and Schizophrenia for School-Age
Children-Present and Lifetime Version (K-SADS-PL): initial relia-
bility and validity data. J Am Acad Child Adolesc Psychiatry.
1997;36:980-8.
115 Polanczyk GV, Eizirik M, Aranovich V, Denardin D, da Silva TL,
da Conceicao TV, et al. Interrater agreement for the schedule
for affective disorders and schizophrenia epidemiological version
for school-age children (K-SADS-E). Rev Bras Psiquiatr. 2003;25:
87-90.
116 Angold A, Erkanli A, Copeland W, Goodman R, Fisher PW, Costello
EJ. Psychiatric diagnostic interviews for children and adolescents: a
comparative study. J Am Acad Child Adolesc Psychiatry.
2012;51:506-17.
117 Goodman R, Ford T, Richards H, Gatward R, Meltzer H. The
Development and Well-Being Assessment: description and initial
validation of an integrated assessment of child and adolescent
psychopathology. J Child Psychol Psychiatry. 2000;41:645-55.
118 Souza IGS, Serra-Pinheiro MA, Mousinho R, Mattos PA. A
Brazilian version of the ‘‘Children’s Interview for Psychiatric
Syndromes’’ (ChIPS). J Bras Psiquiatr. 2009;58:115-8.
119 Weller EB, Weller RA, Fristad MA, Rooney MT, Schecter J.
Children’s Interview for Psychiatric Syndromes (ChIPS). J Am Acad
Child Adolesc Psychiatry. 2000;39:76-84.
120 Shaffer D, Fisher P, Lucas CP, Dulcan MK, Schwab-Stone ME.
NIMH Diagnostic Interview Schedule for Children Version IV (NIMH
DISC-IV): description, differences from previous versions, and
reliability of some common diagnoses. J Am Acad Child Adolesc
Psychiatry. 2000;39:28-38.
121 Reich W. Diagnostic interview for children and adolescents (DICA).
J Am Acad Child Adolesc Psychiatry. 2000;39:59-66.
122 Welner Z, Reich W, Herjanic B, Jung KG, Amado H. Reliability,
validity, and parent-child agreement studies of the Diagnostic
Interview for Children and Adolescents (DICA). J Am Acad Child
Adolesc Psychiatry. 1987;26:649-53.
123 Sherrill JT, Kovacs M. Interview schedule for children and
adolescents (ISCA). J Am Acad Child Adolesc Psychiatry.
2000;39:67-75.
124 Lyneham HJ, Abbott MJ, Rapee RM. Interrater reliability of the
Anxiety Disorders Interview Schedule for DSM-IV: child and parent
version. J Am Acad Child Adolesc Psychiatry. 2007;46:731-6.
125 Silverman WK, Saavedra LM, Pina AA. Test-retest reliability of
anxiety symptoms and diagnoses with the Anxiety Disorders
Interview Schedule for DSM-IV: child and parent versions. J Am
Acad Child Adolesc Psychiatry. 2001;40:937-44.
126 Angold A, Costello EJ. The Child and Adolescent Psychiatric
Assessment (CAPA). J Am Acad Child Adolesc Psychiatry.
2000;39:39-48.
127 Angold A, Prendergast M, Cox A, Harrington R, Simonoff E, Rutter
M. The Child and Adolescent Psychiatric Assessment (CAPA).
Psychol Med. 1995;25:739-53.
128 Egger HL, Erkanli A, Keeler G, Potts E, Walter BK, Angold A. Test-
retest reliability of the Preschool Age Psychiatric Assessment
(PAPA). J Am Acad Child Adolesc Psychiatry. 2006;45:538-49.
129 Merikangas K, Avenevoli S, Costello J, Koretz D, Kessler RC.
National comorbidity survey replication adolescent supplement
(NCS-A): I. background and measures. J Am Acad Child Adolesc
Psychiatry. 2009;48:367-9.
130 Biaggio AMB, Spielberger CD. [Manual of the Portuguese form of
the STAI]. Rio de Janeiro: CEPA; 1983.
131 Spielberger CD. Manual for the State-Trait Anxiety Inventory for
Children. Palo Alto: Consulting Psychologist Press; 1973.
132 Gorayeb MAM, Gorayeb R. [Revised Children’s Manifest Anxiety
Scale (RCMAS) adapt to Portuguese in Brazil]. Temas Psicol.
2008;16:35-45.
133 Reynolds CR, Richmond BO. What I think and feel: a revised
measure of children’s manifest anxiety. J Abnorm Child Psychol.
1997;25:15-20.
134 Beck JS, Beck AT, Jolly JB, Steer RA. Beck Youth Inventories for
children and adolescents: manual. 2nd ed. San Antonio: Harcourt
Assessment, Inc; 2005.
135 The Pediatric Anxiety Rating Scale (PARS): development and
psychometric properties. J Am Acad Child Adolesc Psychiatry.
2002;41:1061-9.
136 Caporino NE, Brodman DM, Kendall PC, Albano AM, Sherrill J,
Piacentini J, et al. Defining treatment response and remission in
child anxiety: signal detection analysis using the pediatric anxiety
rating scale. J Am Acad Child Adolesc Psychiatry. 2013;52:57-67.
137 Birmaher B, Brent DA, Chiappetta L, Bridge J, Monga S, Baugher
M. Psychometric properties of the Screen for Child Anxiety Related
Emotional Disorders (SCARED): a replication study. J Am Acad
Child Adolesc Psychiatry. 1999;38:1230-6.
138 Birmaher B, Khetarpal S, Brent D, Cully M, Balach L, Kaufman J,
et al. The Screen for Child Anxiety Related Emotional Disorders
(SCARED): scale construction and psychometric characteristics. J
Am Acad Child Adolesc Psychiatry. 1997;36:545-53.
139 Desousa DA, Salum GA, Isolan LR, Manfro GG. Sensitivity and
specificity of the screen for Child Anxiety Related Emotional
Disorders (SCARED): a community-based study. Child Psychiatry
Hum Dev. 2013;44:391-9.
140 Isolan L, Salum GA, Osowski AT, Amaro E, Manfro GG.
Psychometric properties of the Screen for Child Anxiety Related
Emotional Disorders (SCARED) in Brazilian children and adoles-
cents. J Anxiety Disord. 2011;25:741-8.
141 DeSousa DA, Petersen CS, Behs R, Manfro GG, Koller SH.
Brazilian Portuguese version of the Spence Children’s Anxiety
Scale (SCAS-Brasil). Trends Psychiatry Psychother. 2012;34:147-
53.
142 Spence SH. A measure of anxiety symptoms among children.
Behav Res Ther. 1998;36:545-66.
143 Spence SH. Structure of anxiety symptoms among children: a
confirmatory factor-analytic study. J Abnorm Psychol.
1997;106:280-97.
144 March JS, Parker JD, Sullivan K, Stallings P, Conners CK. The
Multidimensional Anxiety Scale for Children (MASC): factor
structure, reliability, and validity. J Am Acad Child Adolesc
Psychiatry. 1997;36:554-65.
145 Masia-Warner C, Storch EA, Pincus DB, Klein RG, Heimberg RG,
Liebowitz MR. The Liebowitz social anxiety scale for children and
adolescents: an initial psychometric investigation. J Am Acad Child
Adolesc Psychiatry. 2003;42:1076-84.
146 Gauer GC, Picon P, Davoglio TR, Silva LM, Beidel DC.
Psychometric characteristics of the Brazilian Portuguese version
of Social Phobia and Anxiety Inventory for Children (SPAI-C).
Psico. 2009;40:354-8.
147 Gauer GJ, Picon P, Vasconcellos SJ, Turner SM, Beidel DC.
Validation of the Social Phobia and Anxiety Inventory for Children
(SPAI-C) in a sample of Brazilian children. Braz J Med Biol Res.
2005;38:795-800.
Pediatric anxiety disorders S19
Rev Bras Psiquiatr. 2013;35(Suppl 1)
148 Scaini S, Battaglia M, Beidel DC, Ogliari A. A meta-analysis of the
cross-cultural psychometric properties of the Social Phobia and
Anxiety Inventory for Children (SPAI-C). J Anxiety Disord.
2012:182-8.
149 Beidel DC, Turner SM, Morris TL. A new inventory to assess
childhood social anxiety and phobia: The Social Phobia and Anxiety
Inventory for Children. Psychol Assess. 1995;7:73-9.
150 Freeman J, Flessner CA, Garcia A. The Children’s Yale-Brown
Obsessive Compulsive Scale: reliability and validity for use among
5 to 8 year olds with obsessive-compulsive disorder. J Abnorm
Child Psychol. 2011;39:877-83.
151 Scahill L, Riddle MA, McSwiggin-Hardin M, Ort SI, King RA,
Goodman WK, et al. Children’s Yale-Brown Obsessive Compulsive
Scale: reliability and validity. J Am Acad Child Adolesc Psychiatry.
1997;36:844-52.
152 Storch EA, Murphy TK, Adkins JW, Lewin AB, Geffken GR, Johns
NB, et al. The children’s Yale-Brown obsessive-compulsive scale:
psychometric properties of child- and parent-report formats. J
Anxiety Disord. 2006;20:1055-70.
153 Rosario-Campos MC, Miguel EC, Quatrano S, Chacon P, Ferrao Y,
Findley D, et al. The Dimensional Yale-Brown Obsessive-
Compulsive Scale (DY-BOCS): an instrument for assessing
obsessive-compulsive symptom dimensions. Mol Psychiatry.
2006;11:495-504.
154 Ollendick TH. Reliability and validity of the Revised Fear Surgery
Schedule for Children (FSSC-R). Behav Res Ther. 1983;21:685-92.
155 Masi G, Pari C, Millepiedi S. Pharmacological treatment options for
panic disorder in children and adolescents. Expert Opin
Pharmacother. 2006;7:545-54.
156 Pine DS, Cohen JA. Trauma in children and adolescents: risk and
treatment of psychiatric sequelae. Biol Psychiatry. 2002;51:519-31.
157 Cohen JA, Bukstein O, Walter H, Benson SR, Chrisman A,
Farchione TR, et al. Practice parameter for the assessment and
treatment of children and adolescents with posttraumatic stress
disorder. J Am Acad Child Adolesc Psychiatry. 2010;49:414-30.
158 Ipser JC, Stein DJ, Hawkridge S, Hoppe L. Pharmacotherapy for
anxiety disorders in children and adolescents. Cochrane Database
Syst Rev. 2009:CD005170.
159 DeVeaugh-Geiss J, Moroz G, Biederman J, Cantwell D, Fontaine
R, Greist JH, et al. Clomipramine hydrochloride in childhood and
adolescent obsessive-compulsive disorder--a multicenter trial. J
Am Acad Child Adolesc Psychiatry. 1992;31:45-9.
160 Uthman OA, Abdulmalik J. Comparative efficacy and acceptability
of pharmacotherapeutic agents for anxiety disorders in children and
adolescents: a mixed treatment comparison meta-analysis. Curr
Med Res Opin. 2010;26:53-9.
161 Connolly SD, Suarez L, Sylvester C. Assessment and treatment of
anxiety disorders in children and adolescents. Curr Psychiatry Rep.
2011;13:99-110.
162 Graae F, Milner J, Rizzotto L, Klein RG. Clonazepam in childhood
anxiety disorders. J Am Acad Child Adolesc Psychiatry.
1994;33:372-6.
163 O’Kearney RT, Anstey KJ, von Sanden C. Behavioural and
cognitive behavioural therapy for obsessive compulsive disorder
in children and adolescents. Cochrane Database Syst Rev.
2006:CD004856.
164 Reynolds S, Wilson C, Austin J, Hooper L. Effects of psychotherapy
for anxiety in children and adolescents: a meta-analytic review. Clin
Psychol Rev. 2012;32:251-62.
165 Davis TE, 3rd, May A, Whiting SE. Evidence-based treatment of
anxiety and phobia in children and adolescents: current status and
effects on the emotional response. Clin Psychol Rev. 2011;31:592-602.
166 James A, Soler A, Weatherall R. Cognitive behavioural therapy for
anxiety disorders in children and adolescents. Cochrane Database
Syst Rev. 2005:CD004690.
167 Alvarenga PG, Mastrorosa RS, Rosa´rio MC. Obsessive compulsive
disorder in children and adolescents. In Rey JM, editor. IACAPAP
e-Textbook of Child and Adolescent Mental Health. Geneva:
International Association for Child and Adolescent Psychiatry and
Allied Professions; 2012. p. 1-17.
168 Pediatric OCD Treatment Study (POTS) Team. Cognitive-behavior
therapy, sertraline, and their combination for children and adoles-
cents with obsessive-compulsive disorder: the Pediatric OCD
Treatment Study (POTS) randomized controlled trial. JAMA.
2004;292:1969-76.
169 Garcia AM, Sapyta JJ, Moore PS, Freeman JB, Franklin ME, March
JS, et al. Predictors and moderators of treatment outcome in the
Pediatric Obsessive Compulsive Treatment Study (POTS I). J Am
Acad Child Adolesc Psychiatry. 2011;49:1024-33.
170 March JS, Franklin ME, Leonard H, Garcia A, Moore P, Freeman J,
et al. Tics moderate treatment outcome with sertraline but not
cognitive-behavior therapy in pediatric obsessive-compulsive dis-
order. Biol Psychiatry. 2007;61:344-7.
171 Rosa´rio M, Alvarenga P, Mathis M, Leckman J. Obsessive-
compulsive disorder in childhood. In: Banaschewski T, Rohde L,
editors. Biological child psychiatry - recent trends and develop-
ments. Basel: Karger; 2008. p. 82-94.
172 Norberg MM, Krystal JH, Tolin DF. A meta-analysis of D-
cycloserine and the facilitation of fear extinction and exposure
therapy. Biol Psychiatry. 2008;63:1118-26.
173 Hakamata Y, Lissek S, Bar-Haim Y, Britton JC, Fox NA, Leibenluft
E, et al. Attention bias modification treatment: a meta-analysis
toward the establishment of novel treatment for anxiety. Biol
Psychiatry. 2010;68:982-90.
174 Eldar S, Apter A, Lotan D, Edgar KP, Naim R, Fox NA, et al.
Attention bias modification treatment for pediatric anxiety disorders:
a randomized controlled trial. Am J Psychiatry. 2012;169:213-20.
175 Pittenger C, Kelmendi B, Wasylink S, Bloch MH, Coric V. Riluzole
augmentation in treatment-refractory obsessive-compulsive disor-
der: a series of 13 cases, with long-term follow-up. J Clin
Psychopharmacol. 2008;28:363-7.
176 Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamate-
modulating agent, in the treatment of pathological gambling: a pilot
study. Biol Psychiatry. 2007;62:652-7.
177 Jayakody K, Gunadasa S, Hosker C. Exercise for anxiety disorders:
systematic review. Br J Sports Med. 2013 Jan 7. [Epub ahead of
print]
178 Asmundson GJ, Fetzner MG, Deboer LB, Powers MB, Otto MW,
Smits JA. Let’s get physical: a contemporary review of the anxiolytic
effects of exercise for anxiety and its disorders. Depress Anxiety.
2013;30:362-73.
179 Larun L, Nordheim LV, Ekeland E, Hagen KB, Heian F. Exercise in
prevention and treatment of anxiety and depression among children
and young people. Cochrane Database Syst Rev. 2006:CD004691.
180 Pittler MH, Ernst E. Kava extract for treating anxiety. Cochrane
Database Syst Rev. 2003:CD003383.
181 Miyasaka LS, Atallah AN, Soares BG. Valerian for anxiety
disorders. Cochrane Database Syst Rev. 2006:CD004515.
182 Miyasaka LS, Atallah AN, Soares BG. Passiflora for anxiety
disorder. Cochrane Database Syst Rev. 2007:CD004518.
183 Krisanaprakornkit T, Krisanaprakornkit W, Piyavhatkul N,
Laopaiboon M. Meditation therapy for anxiety disorders.
Cochrane Database Syst Rev. 2006:CD004998.
184 Robinson J, Biley FC, Dolk H. Therapeutic touch for anxiety
disorders. Cochrane Database Syst Rev. 2007:CD006240.
185 Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D,
Ritz L, et al. Evaluation of outcomes with citalopram for depression
using measurement-based care in STAR*D: implications for clinical
practice. Am J Psychiatry. 2006;163:28-40.
186 Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus
HA, et al. Clinical response and risk for reported suicidal
ideation and suicide attempts in pediatric antidepressant treatment:
a meta-analysis of randomized controlled trials. JAMA. 2007;297:
1683-96.
187 Stein DJ, Baldwin DS, Bandelow B, Blanco C, Fontenelle LF, Lee
S, et al. A 2010 evidence-based algorithm for the pharmacotherapy
of social anxiety disorder. Curr Psychiatry Rep. 2010;12:471-7.
188 Gleason MM, Egger HL, Emslie GJ, Greenhill LL, Kowatch RA,
Lieberman AF, et al. Psychopharmacological treatment for very
young children: contexts and guidelines. J Am Acad Child Adolesc
Psychiatry. 2007;46:1532-72.
189 Rapee RM, Kennedy SJ, Ingram M, Edwards SL, Sweeney L.
Altering the trajectory of anxiety in at-risk young children. Am J
Psychiatry. 2010;167:1518-25.
190 Degnan KA, Fox NA. Behavioral inhibition and anxiety disorders:
multiple levels of a resilience process. Dev Psychopathol. 2007;19:
729-46.
GA Salum et al.S20
Rev Bras Psiquiatr. 2013;35(Suppl 1)
191 Fox NA, Henderson HA, Marshall PJ, Nichols KE, Ghera MM.
Behavioral inhibition: linking biology and behavior within a devel-
opmental framework. Annu Rev Psychol. 2005;56:235-62.
192 Hirshfeld-Becker DR, Micco J, Henin A, Bloomfield A, Biederman J,
Rosenbaum J. Behavioral inhibition. Depress Anxiety. 2008;25:
357-67.
193 Smoller JW, Block SR, Young MM. Genetics of anxiety disorders: the
complex road from DSM to DNA. Depress Anxiety. 2009;26:965-75.
194 Domschke K, Deckert J. Genetics of anxiety disorders - status quo
and quo vadis. Curr Pharm Des. 2012;18:5691-8.
195 Gullone E. The development of normal fear: a century of research.
Clin Psychol Rev. 2000;20:429-51.
196 Strawn JR, Sakolsky DJ, Rynn MA. Psychopharmacologic treat-
ment of children and adolescents with anxiety disorders. Child
Adolesc Psychiatr Clin N Am. 2012;21:527-39.
197 Rynn M, Puliafico A, Heleniak C, Rikhi P, Ghalib K, Vidair H.
Advances in pharmacotherapy for pediatric anxiety disorders.
Depress Anxiety. 2011;28:76-87.
198 Peters TE, Connolly S. Psychopharmacologic treatment for
pediatric anxiety disorders. Child Adolesc Psychiatr Clin N Am.
2012;21:789-806.
199 Kar N. Cognitive behavioral therapy for the treatment of post-
traumatic stress disorder: a review. Neuropsychiatr Dis Treat.
2011;7:167-81.
200 Kircanski K, Peris TS, Piacentini JC. Cognitive-behavioral therapy
for obsessive-compulsive disorder in children and adolescents.
Child Adolesc Psychiatr Clin N Am. 2011;20:239-54.
201 Seligman LD, Ollendick TH. Cognitive-behavioral therapy for
anxiety disorders in youth. Child Adolesc Psychiatr Clin N Am.
2011;20:217-38.
Pediatric anxiety disorders S21
Rev Bras Psiquiatr. 2013;35(Suppl 1)
